<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nicardipine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nicardipine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Nicardipine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9697" href="/d/html/9697.html" rel="external">see "Nicardipine: Drug information"</a> and <a class="drug drug_patient" data-topicid="10906" href="/d/html/10906.html" rel="external">see "Nicardipine: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F201178"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Cardene IV</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1027433"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antianginal Agent</span>;</li>
<li>
<span class="list-set-name">Antihypertensive Agent</span>;</li>
<li>
<span class="list-set-name">Calcium Channel Blocker</span>;</li>
<li>
<span class="list-set-name">Calcium Channel Blocker, Dihydropyridine</span></li></ul></div>
<div class="block don drugH1Div" id="F53462519"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b> Limited data available: Preterm and term neonates: Continuous IV infusion: Initial: 0.5 mcg/kg/minute; dosing range: 0.5 to 2 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9135293','lexi-content-ref-12708943','lexi-content-ref-10990112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9135293','lexi-content-ref-12708943','lexi-content-ref-10990112'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F52812539"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7b0208e9-0974-437c-9afa-036cd8b8e3ef">Hypertension, acute severe with life-threatening symptoms</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension</b>
<b>,</b>
<b> acute severe with life-threatening symptoms:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: IV: Bolus dose (optional): Initial: 30 mcg/kg, maximum dose: 2 <b>mg</b>/dose; followed by continuous IV infusion: Initial: 0.5 to 1 mcg/kg/minute; titrate dose to achieve goal blood pressure; rate of infusion may be increased every 15 to 30 minutes; maximum dose: 4 to 5 mcg/kg/minute (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29192011','lexi-content-ref-11149130','lexi-content-ref-11445792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29192011','lexi-content-ref-11149130','lexi-content-ref-11445792'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F52729796"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; based on experience in adult patients, titrate slowly with careful monitoring; dosage adjustment may be necessary.</p></div>
<div class="block dohp drugH1Div" id="F52729797"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling; however, nicardipine is extensively metabolized by the liver. Based on experience in adult patients, consider titrating slowly with monitoring; dosage adjustment may be necessary.</p></div>
<div class="block doa drugH1Div" id="F201182"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9697" href="/d/html/9697.html" rel="external">see "Nicardipine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f7069f2f-716f-4539-aa40-39abab340257">Acute aortic syndromes/acute aortic dissection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute aortic syndromes/acute aortic dissection (adjunctive agent) (off-label use)</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Manage patients on an emergency basis (including operative assessment) by first controlling pain with IV opioids and heart rate (target 60 to 80 beats per minute) with a parenteral beta blocker (eg, esmolol) while targeting systolic BP of ≤120 mm Hg (or lowest tolerated pressure without compromising perfusion). If systolic BP remains elevated after heart rate is controlled at 60 to 80 beats per minute with beta-blockade, may consider adding a vasodilator (eg, nicardipine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36322642','lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36322642','lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion</b>: Initial: 5 mg/hour; titrate by 2.5 mg/hour at 5- to 15-minute intervals to achieve target blood pressure; maximum dose: 15 mg/hour. Invasive blood pressure monitoring, preferably via arterial line, in a critical care unit is recommended for appropriate dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-31693807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-31693807'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c4321da4-681e-4b90-ad74-21ac966a29fd">Acute ischemic stroke, BP management with reperfusion therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute ischemic stroke, BP management with reperfusion therapy (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Prior to reperfusion therapy (thrombolytic and/or mechanical thrombectomy), maintain a target BP of <b>≤185/110 mm Hg. </b>If BP remains &gt;185/110 mm Hg, do <b>not</b> administer thrombolytic. During and 24 hours after start of thrombolytic therapy, maintain a target BP of <b>≤180/105 mm Hg</b>; if hypertension is refractory or diastolic BP &gt;140 mm Hg, consider alternative therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> Initial: 5 mg/hour; titrate by 2.5 mg/hour at 5- to 15-minute intervals (maximum dose: 15 mg/hour) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31662037']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31662037'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c263a8d4-f2ef-49a8-a963-6b87a475dbec">Angina</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angina:</b>
<b>Oral:</b> 20 mg 3 times daily; usual dosage: 20 to 40 mg 3 times daily (allow ≥3 days between dose increases).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b>
<b>Oral:</b> Initial: 20 mg 3 times daily; usual dosage: 20 to 40 mg 3 times daily (allow ≥3 days between dose increases).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a669e060-0890-4fb4-a8f4-02d01c746a9b">Hypertensive emergency</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note</b>
<b>: </b>In general, reduce mean arterial blood pressure gradually by ~10% to 20% over the first hour, then by an additional 5% to 15% over the next 23 hours, unless there is a compelling indication (eg, acute aortic dissection, severe preeclampsia, eclampsia) for more rapid blood pressure and heart rate control. Invasive blood pressure monitoring is recommended for appropriate dose titration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Elliott.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Elliott.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> Initial: 5 mg/hour; titrate by 2.5 mg/hour at 5- to 15-minute intervals to achieve target blood pressure; maximum dose: 15 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-31693807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-31693807'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e9f708dd-ef5e-4e74-8eb4-bbad8f556048">Hypertensive emergency in pregnancy or postpartum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertensive emergency in pregnancy or postpartum (including acute-onset severe hypertension in preeclampsia/eclampsia) (off-label use) (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For acute-onset, severe, persistent hypertension (eg, systolic BP ≥160 mm Hg or diastolic BP ≥110 mm Hg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32443079']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32443079'])">Ref</a></span>). Nicardipine may be considered in patients with persistently high BP despite administration of first-line agents (eg, labetalol, hydralazine, nifedipine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30575676','lexi-content-ref-August.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30575676','lexi-content-ref-August.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> Initial: 5 mg/hour; titrate by 0.5 to 1 mg/hour at 15-minute intervals to achieve target BP; maximum dose: 15 mg/hour (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-August.1','lexi-content-ref-25721057','lexi-content-ref-31841131','lexi-content-ref-32388119']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-August.1','lexi-content-ref-25721057','lexi-content-ref-31841131','lexi-content-ref-32388119'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="31b3d7ad-f085-452f-a832-866c94a87948">Intracerebral hemorrhage, acute, blood pressure management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracerebral hemorrhage, acute, blood pressure management (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use in patients with mild to moderate intracerebral hemorrhage with a presenting systolic BP ≥150 mm Hg; acute lowering to &lt;130 mm Hg is potentially harmful (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35579034']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35579034'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Continuous IV infusion:</b> Initial: 5 mg/hour; titrate by 2.5 mg/hour at 5- to 15-minute intervals to target systolic BP (maximum dose: 15 mg/hour) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-35579034','lexi-content-ref-17967691','lexi-content-ref-23055089']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-35579034','lexi-content-ref-17967691','lexi-content-ref-23055089'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0e395518-1fe9-4e98-b264-8cef989eaea2">Subarachnoid hemorrhage, blood pressure management</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Subarachnoid hemorrhage, blood pressure management (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Optimal therapy is not well established. Cautious use of antihypertensive therapy to decrease the risk of rebleeding may be appropriate in some patients with systolic BP &gt;160 mm Hg or mean arterial pressure &gt;110 mm Hg with adequate cerebral perfusion pressure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22556195','lexi-content-ref-21773873']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22556195','lexi-content-ref-21773873'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous IV infusion:</b> Initiate 5 mg/hour; titrate by 2.5 mg/hour at 5- to 15-minute intervals to goal target systolic BP or mean arterial pressure (maximum dose: 15 mg/hour) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17967691']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17967691'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Substitution for oral therapy (approximate equivalents):</b></p>
<p style="text-indent:-2em;margin-left:4em;">20 mg every 8 hours oral, equivalent to 0.5 mg/hour IV infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">30 mg every 8 hours oral, equivalent to 1.2 mg/hour IV infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">40 mg every 8 hours oral, equivalent to 2.2 mg/hour IV infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Conversion to oral antihypertensive agent: </b>Initiate oral antihypertensive at the same time that IV nicardipine is discontinued; if transitioning to oral nicardipine, start oral nicardipine 1 hour prior to IV discontinuation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990619"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Initial: 20 mg 3 times daily; titrate slowly.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: There are no specific dosage adjustments provided in the manufacturer's labeling; titrate slowly with careful monitoring; dosage adjustment may be necessary.</p></div>
<div class="block doha drugH1Div" id="F50987860"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Initial: 20 mg twice daily; titrate slowly.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: There are no specific dosage adjustments provided in the manufacturer's labeling; titrate slowly with monitoring; dosage adjustment may be necessary.</p></div>
<div class="block adr drugH1Div" id="F201145"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (6% to 10%), pedal edema (dose related; 7% to 8%), exacerbation of angina pectoris (dose related; 6%), hypotension (IV 6%), palpitations (3% to 4%), tachycardia (1% to 4%), chest pain (IV 1%), extrasystoles (IV 1%), hemopericardium (IV 1%), hypertension (IV 1%), supraventricular tachycardia (IV 1%), edema (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (6% to 15%), dizziness (4% to 7%), hypoesthesia (1%), intracranial hemorrhage (1%), pain (1%), somnolence (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (1%), skin rash (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypokalemia (IV 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea and vomiting (IV 5%), nausea (2%), dyspepsia (≤2%), abdominal pain (IV 1%), xerostomia (≤1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hematuria (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection site reaction (IV 1%), pain at injection site (IV 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Weakness (4% to 6%), myalgia (1%), paresthesia (1%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal dreams, abnormal hepatic function tests, abnormal vision, angina pectoris, anxiety, arthralgia, atrial fibrillation (not distinguishable from natural history of atherosclerotic vascular disease), atrioventricular block, atypical chest pain, blurred vision, cerebral ischemia (not distinguishable from natural history of atherosclerotic vascular disease), confusion, conjunctivitis, constipation, deep vein thrombophlebitis, depression, depression of ST segment on ECG, dyspnea, ear disease, ECG abnormal, fever, gingival hyperplasia, heart block (not distinguishable from natural history of atherosclerotic vascular disease), hot flash, hyperkinesia, hypersensitivity reaction, hypertonia, hypophosphatemia, impotence, infection, insomnia, inversion T wave on ECG, malaise, myocardial infarction (chronic therapy; may be due to disease progression), neck pain, nervousness, nocturia, orthostatic hypotension, oxygen saturation decreased (possible pulmonary shunting), parotitis, pericarditis (not distinguishable from natural history of atherosclerotic vascular disease), peripheral vascular disease, psoriasis (Song 2021), respiratory tract disease, rhinitis, sinus node dysfunction (chronic therapy; may be due to disease progression), sinusitis, sore throat, sustained tachycardia, syncope, thrombocytopenia, tinnitus, tremor, urinary frequency, ventricular extrasystoles, ventricular tachycardia, vertigo, vomiting</p></div>
<div class="block coi drugH1Div" id="F201159"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to nicardipine or any component of the formulation; advanced aortic stenosis</p></div>
<div class="block war drugH1Div" id="F201142"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angina/MI: Increased angina (frequency, duration, or severity) and/or MI has occurred. Reflex tachycardia may occur resulting in angina and/or MI in patients with obstructive coronary disease, especially in the absence of concurrent beta blockade.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension/syncope: Symptomatic hypotension with or without syncope may rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Avoid systemic hypotension in acute cerebral infarction or hemorrhage. Close monitoring of heart rate and blood pressure, especially during initial therapy and dosage titration, is required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Peripheral edema: A common side effect is peripheral edema (dose-dependent); occurs within 2 to 3 weeks of starting therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tachycardia: May occur; close monitoring of heart rate is required.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic stenosis: Use with caution in patients with mild to moderate aortic stenosis; may reduce coronary perfusion resulting in ischemia. Use is contraindicated in patients with advanced aortic stenosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure: Use in patients with heart failure (HF) or severe left ventricular dysfunction, particularly with concomitant beta-blockade, may experience worsened symptoms of HF due to mild negative inotropic effects of nicardipine. The ACC/AHA heart failure guidelines recommend to avoid use in patients with heart failure due to lack of benefit and/or worse outcomes with calcium channel blockers in general (FDA 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment or reduced hepatic blood flow. Consider lower starting dose and closely monitor response.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Use with caution in patients with hypertrophic cardiomyopathy and left ventricular outflow tract obstruction since reduction in afterload may worsen symptoms associated with this condition (AHA/ACC [Ommen 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment. Increase dose cautiously in patients with kidney impairment since clearance of nicardipine is diminished in this population.</p>
<p style="text-indent:0em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion sites: To minimize infusion site reactions, peripheral infusion sites (for IV therapy) should be changed every 12 hours; use of arteries or small peripheral veins should be avoided.</p>
<p style="text-indent:-2em;margin-left:4em;">• Withdrawal: Abrupt withdrawal may cause rebound angina in patients with CAD.</p></div>
<div class="block foc drugH1Div" id="F201152"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 30 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/200 mL in NaCl 0.9% (200 mL); 40 mg/200 mL in NaCl 0.9% (200 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Cardene IV: 20 mg (200 mL); 40 mg (200 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/mL (10 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 2.5 mg/mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F201138"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F201161"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (niCARdipine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $15.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">30 mg (per each): $22.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Cardene IV Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/200 mL 0.86% (per mL): $0.35</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/200 mL 0.83% (per mL): $0.57</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (niCARdipine HCl in NaCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/200 mL 0.9% (per mL): $0.49</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg/200 mL 0.9% (per mL): $0.98</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (niCARdipine HCl Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg/mL (per mL): $2.29 - $25.29</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block admp drugH1Div" id="F52613418"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Administer by slow IV continuous infusion through a central line or large peripheral vein; avoid extravasation. Peripheral infusion sites should be changed every 12 hours to minimize venous irritation.</p>
<p style="text-indent:-2em;margin-left:4em;">Vial: Must be diluted prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Premixed solutions: No further dilution needed. For single use only; discard any unused portion. Use only if solution is clear; per manufacturer's labeling, do not add nicardipine solution with other medications in the same line or in premixed container.</p></div>
<div class="block adm drugH1Div" id="F201156"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer without regards to meals.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Administer as a slow continuous infusion via central line or through a large peripheral vein. Peripheral venous irritation may be minimized by changing the site of infusion every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Premixed bags: Do not combine or run in the same line as other medications.</p></div>
<div class="block uicp drugH1Div" id="F14472950"><span class="drugH1">Usual Infusion Concentrations: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Premixed solutions available.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV infusion:</b> 100 <b>mcg</b>/mL, 200 <b>mcg</b>/mL, <b>or </b>500 <b>mcg</b>/mL.</p></div>
<div class="block sts drugH1Div" id="F201173"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">IV:</p>
<p style="text-indent:-2em;margin-left:4em;">Premixed bags: Store at 20°C to 25°C (68°F to 77°F). Protect from light and excessive heat. Do not freeze.</p>
<p style="text-indent:-2em;margin-left:4em;">Vials: Store at 20°C to 25°C (68°F to 77°F). Protect from light. Freezing does not adversely affect the product, but exposure to elevated temperatures should be avoided. Diluted solution (0.1 mg/mL)  in D5W with KCl 40 mEq, D5<sup>1</sup>/<sub>2</sub>NS, D5NS, D5W, NS, or <sup>1</sup>/<sub>2</sub>NS is stable at room temperature for 24 hours in glass or PVC containers. Stability has also been demonstrated at room temperature at concentrations up to 0.5 mg/mL in PVC containers for 24 hours or in glass containers for up to 7 days (Baaske 1996).</p>
<p style="text-indent:-2em;margin-left:2em;">Oral: Store at room temperature. Protect from light.</p></div>
<div class="block usep drugH1Div" id="F53568014"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Treatment of chronic stable angina and treatment of hypertension (FDA approved in adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: Short-term treatment of hypertension when oral treatment is not feasible (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F201224"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">NiCARdipine may be confused with niacinamide, NIFEdipine, niMODipine</p>
<p style="text-indent:-2em;margin-left:4em;">Cardene may be confused with Cardizem, Cardura, codeine</p>
<p style="text-indent:-2em;margin-left:4em;">Cardene I.V. may be confused with Nexterone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Administration issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Significant differences exist between oral and IV dosing. Use caution when converting from one route of administration to another.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Cardene [US, Great Britain, Netherlands] may be confused with Cardem brand name for celiprolol [Spain]; Cardin brand name for simvastatin [Poland]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F201209"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP2C8 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F201147"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetidine: May increase the serum concentration of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of CycloSPORINE (Systemic). CycloSPORINE (Systemic) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of NiCARdipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of NiCARdipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers. Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of NiCARdipine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhalational Anesthetics: May enhance the hypotensive effect of Calcium Channel Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: NiCARdipine may enhance the QTc-prolonging effect of Levoketoconazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Sulfate: May enhance the adverse/toxic effect of Calcium Channel Blockers (Dihydropyridine). Specifically, the risk of hypotension or muscle weakness may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Melatonin: May diminish the antihypertensive effect of Calcium Channel Blockers (Dihydropyridine).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SUNItinib: NiCARdipine may increase the serum concentration of SUNItinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Calcium Channel Blockers (Dihydropyridine) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F201175"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Serum concentrations/toxicity of nicardipine may be increased by grapefruit juice. Management: Monitor for excessive hemodynamic (ie, blood pressure, heart rate) response to nicardipine in patients who consume grapefruit juice.</p></div>
<div class="block rep_considerations drugH1Div" id="F58529354"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be continued in patients trying to conceive. Nicardipine is not considered a preferred agent for use in pregnant patients; consider transitioning to a preferred agent in patients planning to become pregnant (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p></div>
<div class="block pri drugH1Div" id="F201162"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Nicardipine has limited placental transfer following maternal oral and IV administration (Bartels 2007; Carbonne 1993; Matsumura 2014).</p>
<p style="text-indent:0em;margin-top:2em;">Nicardipine has been shown to decrease maternal blood pressure without significant changes on placental perfusion or fetal hemodynamics (Cornette 2016). Although effective for the treatment of hypertension in pregnancy, nicardipine may have an increased risk of adverse maternal events (eg, headache, nausea, tachycardia) in comparison to other agents (Nooij 2014). Cases of acute pulmonary edema have been reported following use as a tocolytic (Melis 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, premature delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated chronic hypertension may also increase the risks of adverse maternal outcomes, including gestational diabetes, preeclampsia, delivery complications, stroke, and myocardial infarction (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Patients with preexisting hypertension may continue their medication during pregnancy unless contraindications exist (ESC [Regitz-Zagrosek 2018]). When treatment of chronic hypertension during pregnancy is initiated during pregnancy, agents other than nicardipine may be preferred (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018], SOGC [Magee 2022]). Nicardipine may be used as an alternative agent for the treatment of acute-onset, severe hypertension in patients who are pregnant (ACOG 2019; ESC [Cífková 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53568015"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure (continuously for IV infusion), heart rate, liver and kidney function, infusion site for extravasation.</p></div>
<div class="block pha drugH1Div" id="F201141"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Inhibits calcium ion from entering the “slow channels” or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization, producing a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina</p></div>
<div class="block phk drugH1Div" id="F201158"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: IV: Within minutes (constant infusion); Oral: 0.5 to 2 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Oral: 1 to 2 hours; IV continuous infusion: 50% of the maximum effect is seen by 45 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: ≤8 hours; upon discontinuation of continuous infusion, a 50% decrease in effect is seen in ~30 minutes with gradual discontinuing antihypertensive effects for ~50 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: ≤8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: ~100%, but large first-pass effect.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 8.3 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;95%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; extensive first-pass effect (saturable); major pathway is via cytochrome P450 isoenzyme CYP3A4, 2C8, and 2D6.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral: ~35%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Follows dose-dependent (nonlinear) pharmacokinetics; “apparent” or calculated half-life is dependent upon serum concentrations.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Half-life over the first 8 hours is 2 to 4 hours; terminal half-life: 8.6 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">IV: After IV infusion, serum concentrations decrease tri-exponentially; alpha half-life: 3 minutes; beta half-life: 45 minutes; terminal half-life: 14 hours (<b>Note:</b> Terminal half-life can only be seen after long-term infusions).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 30 to 120 minutes (mean: 1 hour).</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (oral: 60% as metabolites; IV: 49% as metabolites; &lt;1% as unchanged drug); feces (oral: 35%; IV: 43%).</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Decreased in patients with hepatic impairment; may be decreased in patients with kidney impairment.</p></div>
<div class="block phksp drugH1Div" id="F51154896"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function:</p>
<p style="text-indent:-2em;margin-left:4em;">IV: Significantly lower systemic clearance and higher AUC in patients with mild to moderate kidney impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: C<sub>max</sub> and AUC were ~2-fold higher in patients with mild kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with severe hepatic impairment, plasma concentrations were elevated and the half-life was prolonged.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F201163"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Nicardipine | Rydene</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Loxen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Nicardipin labatec</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Loxen</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">BEI ER PING | Dan yi | Ka rong | Ka shu tai | Pei er | Perdipine | Xin shu li da</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Micard | Pelcard</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Nerdipina</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Loxen | Loxen L P | Nicardipine Aguettant | Nicardipine Arrow | Nicardipine Dci</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Cardene | Nicardipine | Nicardipine kent</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Nicardipine Aguettant</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Blistra | Carsive | Dipitenz | Loxen | Nicardipine | Nicardipine HCL | Nidaven | Perdipine | Tensilo | Verdif</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Cardene</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bionicard | Cardioten | Neucor | Nicant | Nicardal | Nicardipina | Nicardipina dorom | Nicardipina drm | Nicarpin | Nicaven | Perdipina | Ranvil | Vasodin</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Apodipine | Aprovan | Aprovan kobayashi | Aprovan teisan | Carbadin la | Cepadipin | Isedipeal | Kenicalnon | Nicadirus l | Nicarpine sawai | Nicodel | Nisutadil | Palpedinon | Paltidel l | Perdipine | Radistmin | Radistmin taiyo | Salipex la | Salipex nichiiko</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Binicapin | Dong a perdipine | Dongkoo nicardipine hcl | Nicarpin | Perdipine</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Nicardipine</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Loxen</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Rydene</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Loxen | Vasodin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Ridene</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Cardepine | Vasonase</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Cardene</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Cardepine | Cardilon | Cardimed | Nicard | Nicardilex | Nicardin | Nicaright | Nicarpin | Nicarpine | Noticanz</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Antagonil | Cardene</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Cardene | Nicardipine HCL</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Loxen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Cardene | Cardene SR</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Cardibloc</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Benicardine | Binicapin | Cardepine | Holdipine | Nicardipine | Nidepine</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Loxen | Nicardipine | Nicardipine medis | Vasodin</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Ninax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Holdipine premixed | Nicardipine | Nicarpine | Perdipine</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17431204">
<a name="17431204"></a>Adams HP, del Zoppo G, Alberts MJ, et al. Guidelines for the Early Management of Adults With Ischemic Stroke: A Guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups. <i>Stroke.</i> 2007;38(5):1655-1711. http://stroke.ahajournals.org/cgi/reprint/STROKEAHA.107.181486 
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/17431204/pubmed" id="17431204" target="_blank">17431204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32443079">
<a name="32443079"></a>American College of Obstetricians and Gynecologists (ACOG). Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. <i>Obstet Gynecol.</i> 2020;135(6):e237-e260. doi:10.1097/AOG.0000000000003891<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/32443079/pubmed" id="32443079" target="_blank">32443079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.1">
<a name="ASHP.1"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated January 2021. Accessed January 24, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ASHP.2">
<a name="ASHP.2"></a>American Society of Health-System Pharmacists (ASHP). Pediatric continuous infusion standards. Available at https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/Pediatric-Infusion-Standards.ashx. Updated August 2022. Accessed August 15, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17692738">
<a name="17692738"></a>Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction: Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, The Society of Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. <i>J Am Coll Cardiol.</i> 2007;50(7):e1-e157.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/17692738/pubmed" id="17692738" target="_blank">17692738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-August.1">
<a name="August.1"></a>August P. Treatment of hypertension in pregnant and postpartum patients. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8827237">
<a name="8827237"></a>Baaske DM, DeMay JF, Latona CA, et al. Stability of Nicardipine Hydrochloride in Intravenous Solutions. <i>Am J Health Syst Pharm.</i> 1996;53(14):1701-1705.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/8827237/pubmed" id="8827237" target="_blank">8827237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17166219">
<a name="17166219"></a>Bartels PA, Hanff LM, Mathot RA, et al. Nicardipine in Pre-Eclamptic Patients: Placental Transfer and Disposition in Breast Milk. <i>BJOG.</i> 2007;114(2):230-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/17166219/pubmed" id="17166219" target="_blank">17166219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17478736">
<a name="17478736"></a>Broderick J, Connolly S, Feldmann E, et al; American Heart Association; American Stroke Association Stroke Council; High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. <i>Stroke</i>. 2007;38(6):2001-2023. doi:10.1161/STROKEAHA.107.183689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/17478736/pubmed" id="17478736" target="_blank">17478736</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8497354">
<a name="8497354"></a>Carbonne B, Jannet D, Touboul C, Khelifati Y, Milliez J. Nicardipine treatment of hypertension during pregnancy. <i>Obstet Gynecol</i>. 1993;81(6):908-914.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/8497354/pubmed" id="8497354" target="_blank">8497354</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cardene.1">
<a name="Cardene.1"></a>Cardene IV (nicardipine) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; November 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22556195">
<a name="22556195"></a>Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al; American Heart Association Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Council on Cardiovascular Surgery and Anesthesia; Council on Clinical Cardiology. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2012;43(6):1711-1737. doi:10.1161/STR.0b013e3182587839<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/22556195/pubmed" id="22556195" target="_blank">22556195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721057">
<a name="25721057"></a>Cornette J, Buijs EA, Duvekot JJ, et al. Hemodynamic effects of intravenous nicardipine in severely pre-eclamptic women with a hypertensive crisis. <i>Ultrasound Obstet Gynecol</i>. 2016;47(1):89-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/25721057/pubmed" id="25721057" target="_blank">25721057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21773873">
<a name="21773873"></a>Diringer MN, Bleck TP, Claude Hemphill J 3rd, et al; Neurocritical Care Society. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. <i>Neurocrit Care</i>. 2011;15(2):211-240. doi:10.1007/s12028-011-9605-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/21773873/pubmed" id="21773873" target="_blank">21773873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11259889">
<a name="11259889"></a>Dorman T, Thompson DA, Breslow MJ, et al. Nicardipine versus Nitroprusside for Breakthrough Hypertension Following Carotid Endarterectomy. <i>J Clin Anesth.</i> 2001;13(1):16-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/11259889/pubmed" id="11259889" target="_blank">11259889</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12209278">
<a name="12209278"></a>Elatrous S, Nouira S, Ouanes Besbes L, et al. Short-term treatment of severe hypertension of pregnancy: prospective comparison of nicardipine and labetalol. <i>Intensive Care Med</i>. 2002;28(9):1281-1286. doi:10.1007/s00134-002-1406-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/12209278/pubmed" id="12209278" target="_blank">12209278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Elliott.2020">
<a name="Elliott.2020"></a>Elliott WJ, Vernon J. Evaluation and treatment of hypertensive emergencies in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10669188">
<a name="10669188"></a>Erstad BL, Barletta JF. Treatment of Hypertension in the Perioperative Patient. <i>Ann Pharmacother.</i> 2000;34(1):66-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/10669188/pubmed" id="10669188" target="_blank">10669188</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation.</i> 2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29192011">
<a name="29192011"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents [published correction appears in <i>Pediatrics</i>. 2017;140(6):e20173035 and <i>Pediatrics</i>. 2018;142(3):e20181739]. <i>Pediatrics</i>. 2017;140(3):e20171904.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/29192011/pubmed" id="29192011" target="_blank">29192011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11445792">
<a name="11445792"></a>Flynn JT, Mottes TA, Brophy PD, Kershaw DB, Smoyer WE, Bunchman TE. Intravenous nicardipine for treatment of severe hypertension in children. <i>J Pediatr</i>. 2001;139(1):38-43. doi:10.1067/mpd.2001.114030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/11445792/pubmed" id="11445792" target="_blank">11445792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11149130">
<a name="11149130"></a>Flynn JT, Pasko DA. Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension. <i>Pediatr Nephrol.</i> 2000;15(3-4):302-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/11149130/pubmed" id="11149130" target="_blank">11149130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24243703">
<a name="24243703"></a>Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/24243703/pubmed" id="24243703" target="_blank">24243703</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9135293">
<a name="9135293"></a>Gouyon JB, Geneste B, Semama DS, et al. Intravenous Nicardipine in Hypertensive Preterm Infants. <i>Arch Dis Child Fetal Neonatal Ed.</i> 1997;76(2):F126-F127.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/9135293/pubmed" id="9135293" target="_blank">9135293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35579034">
<a name="35579034"></a>Greenberg SM, Ziai WC, Cordonnier C, et al; American Heart Association/American Stroke Association. 2022 guideline for the management of patients with spontaneous intracerebral hemorrhage: a guideline from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2022;53(7):e282-e361. doi:10.1161/STR.0000000000000407<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/35579034/pubmed" id="35579034" target="_blank">35579034</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26022637">
<a name="26022637"></a>Hemphill JC 3rd, Greenberg SM, Anderson CS, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2015;46(7):2032-2060. doi:10.1161/STR.0000000000000069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/26022637/pubmed" id="26022637" target="_blank">26022637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36322642">
<a name="36322642"></a>Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology joint committee on clinical practice guidelines. <i>Circulation.</i> 2022;146(24):e334-e482. doi:10.1161/CIR.0000000000001106<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/36322642/pubmed" id="36322642" target="_blank">36322642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24352797">
<a name="24352797"></a>James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8) [published online December 18, 2013]. <i>JAMA</i>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/24352797/pubmed" id="24352797" target="_blank">24352797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jarreau.1">
<a name="Jarreau.1"></a>Jarreau PH, Le Beller C, Guillonneau M, Jacqz-Aigrain E. Excretion of nicardipine in human milk. <i>Paediatr Perinat Drug Ther</i>. 2000;4:28-30.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956227">
<a name="20956227"></a>Jauch EC, Cucchiara B, Adeoye O, et al. Part 11: Adult Stroke: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation.</i> 2010;122(18)(suppl 3):818-828.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/20956227/pubmed" id="20956227" target="_blank">20956227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23370205">
<a name="23370205"></a>Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. <i>Stroke.</i> 2013;44(3):870-947.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/23370205/pubmed" id="23370205" target="_blank">23370205</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22990355">
<a name="22990355"></a>Koga M, Toyoda K, Yamagami H, et al; Stroke Acute Management with Urgent Risk-factor Assessment and Improvement Study Investigators. Systolic blood pressure lowering to 160 mmHg or less using nicardipine in acute intracerebral hemorrhage: a prospective, multicenter, observational study (the Stroke Acute Management with Urgent Risk-factor Assessment and Improvement-Intracerebral Hemorrhage study). <i>J Hypertens</i>. 2012;30(12):2357-2364. doi:10.1097/HJH.0b013e328359311b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/22990355/pubmed" id="22990355" target="_blank">22990355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23760911">
<a name="23760911"></a>Liu-DeRyke X, Levy PD, Parker D Jr, Coplin W, Rhoney DH. A prospective evaluation of labetalol versus nicardipine for blood pressure management in patients with acute stroke. <i>Neurocrit Care</i>. 2013;19(1):41-47. doi:10.1007/s12028-013-9863-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/23760911/pubmed" id="23760911" target="_blank">23760911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17565029">
<a name="17565029"></a>Marik PE, Varon J. Hypertensive crises: challenges and management. <i>Chest.</i> 2007;131(6);1949-1962.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/17565029/pubmed" id="17565029" target="_blank">17565029</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24131296">
<a name="24131296"></a>Matsumura H, Takagi K, Seki H, et al. Placental transfer of intravenous nicardipine and disposition into breast milk during the control of hypertension in women with pre-eclampsia. <i>Hypertens Pregnancy</i>. 2014;33(1):93-101.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/24131296/pubmed" id="24131296" target="_blank">24131296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12708943">
<a name="12708943"></a>McBride BF, White CM, Campbell M, et al. Nicardipine to control neonatal hypertension during extracorporeal membrane oxygen support. <i>Ann Pharmacother.</i> 2003;37(5):667-670.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/12708943/pubmed" id="12708943" target="_blank">12708943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25845714">
<a name="25845714"></a>Melis M, Cupelli A, Sottosanti L, et al. Off-label use of nicardipine as tocolytic and acute pulmonary oedema: a post-marketing analysis of adverse drug reaction reports in EudraVigilance. <i>Pharmacoepidemiol Drug Saf</i>. 2015;24(11):1220-1224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/25845714/pubmed" id="25845714" target="_blank">25845714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10990112">
<a name="10990112"></a>Milou C, Debuche-Benouachkou V, Semama DS, et al. Intravenous nicardipine as a first-line antihypertensive drug in neonates. <i>Intensive Care Med. </i> 2000;26(7):956-958.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/10990112/pubmed" id="10990112" target="_blank">10990112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17967691">
<a name="17967691"></a>Mocco J, Rose JC, Komotar RJ, Mayer SA. Blood pressure management in patients with intracerebral and subarachnoid hemorrhage. <i>Neurosurg Clin N Am</i>. 2006;17(suppl 1):25-40. doi:10.1016/s1042-3680(06)80005-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/17967691/pubmed" id="17967691" target="_blank">17967691</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). Hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Nicardipine.1">
<a name="Nicardipine.1"></a>Nicardipine hydrochloride capsules [prescribing information]. Mahwah, NJ: Glenmark Pharmaceuticals Inc USA; September 2022.</div>
</li>
<li>
<div class="reference">
                  Nicardipine hydrochloride injection [prescribing information]. Lehi, UT: Civica, Inc; May 2020.</div>
</li>
<li>
<div class="reference">
                  Nicardipine hydrochloride injection solution [prescribing information]. Eatontown, NJ: Hikma Pharmaceuticals USA Inc; July 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20591204">
<a name="20591204"></a>Nij Bijvank SW, Duvekot JJ. Nicardipine for the treatment of severe hypertension in pregnancy: a review of the literature. <i>Obstet Gynecol Surv</i>. 2010;65(5):341-347. doi:10.1097/OGX.0b013e3181e2c795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/20591204/pubmed" id="20591204" target="_blank">20591204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35707886">
<a name="35707886"></a>Nij Bijvank SW, Hengst M, Cornette JC, et al. Nicardipine for treating severe antepartum hypertension during pregnancy: Nine years of experience in more than 800 women. <i>Acta Obstet Gynecol Scand</i>. 2022;101(9):1017-1025. doi:10.1111/aogs.14406<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/35707886/pubmed" id="35707886" target="_blank">35707886</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi:10.1161/CIR.0000000000000029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24720593">
<a name="24720593"></a>Nooij LS, Visser S, Meuleman T, Vos P, Roelofs R, de Groot CJ. The optimal treatment of severe hypertension in pregnancy: update of the role of nicardipine. <i>Curr Pharm Biotechnol</i>. 2014;15(1):64-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/24720593/pubmed" id="24720593" target="_blank">24720593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23055089">
<a name="23055089"></a>Ortega-Gutierrez S, Thomas J, Reccius A, et al. Effectiveness and safety of nicardipine and labetalol infusion for blood pressure management in patients with intracerebral and subarachnoid hemorrhage. <i>Neurocrit Care</i>. 2013;18(1):13-19. doi:10.1007/s12028-012-9782-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/23055089/pubmed" id="23055089" target="_blank">23055089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9131913">
<a name="9131913"></a>Pascual-Castroviejo I, Pascual Pascual SI. Nicardipine-induced gingival hyperplasia. <i>Neurologia.</i> 1997;12(1):37-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/9131913/pubmed" id="9131913" target="_blank">9131913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31693807">
<a name="31693807"></a>Peixoto AJ. Acute severe hypertension. <i>N Engl J Med</i>. 2019;381(19):1843-1852. doi:10.1056/NEJMcp1901117<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/31693807/pubmed" id="31693807" target="_blank">31693807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31662037">
<a name="31662037"></a>Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. <i>Stroke</i>. 2019;50(12):e344-e418. doi:10.1161/STR.0000000000000211<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/31662037/pubmed" id="31662037" target="_blank">31662037</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32388119">
<a name="32388119"></a>Qi H, Qin J, Ren L, et al. Efficacy of low-dose nicardipine for emergent treatment of severe postpartum hypertension in maternal intensive care units: an observational study.<i> Pregnancy Hypertens.</i> 2020;21:43-49. doi:10.1016/j.preghy.2020.04.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/32388119/pubmed" id="32388119" target="_blank">32388119</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27276234">
<a name="27276234"></a>Qureshi AI, Palesch YY, Barsan WG, et al; ATACH-2 Trial Investigators and the Neurological Emergency Treatment Trials Network. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. <i>N Engl J Med</i>. 2016;375(11):1033-1043. doi: 10.1056/NEJMoa1603460.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/27276234/pubmed" id="27276234" target="_blank">27276234</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10567194">
<a name="10567194"></a>Randomized Double-Blind Comparison of a Calcium Antagonist and a Diuretic in Elderly Hypertensives. National Intervention Cooperative Study in Elderly Hypertensives Study Group. <i>Hypertension.</i> 1999;34(5):1129-1133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/10567194/pubmed" id="10567194" target="_blank">10567194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18728576">
<a name="18728576"></a>Roitberg BZ, Hardman J, Urbaniak K, et al. Prospective randomized comparison of safety and efficacy of nicardipine and nitroprusside drip for control of hypertension in the neurosurgical intensive care unit. <i>Neurosurgery</i>. 2008;63(1):115-120. doi: 10.1227/01.NEU.0000335078.62599.14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/18728576/pubmed" id="18728576" target="_blank">18728576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Singer.2020">
<a name="Singer.2020"></a>Singer RJ, Ogilvy CS, Rordorf G. Aneurysmal subarachnoid hemorrhage: Treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 16, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34611920">
<a name="34611920"></a>Song G, Yoon HY, Yee J, Kim MG, Gwak HS. Antihypertensive drug use and psoriasis: a systematic review, meta- and network meta-analysis. <i>Br J Clin Pharmacol</i>. Published online October 5, 2021. doi:10.1111/bcp.15060<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/34611920/pubmed" id="34611920" target="_blank">34611920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8135450">
<a name="8135450"></a>Steele RM, Schuna AA, Schreiber RT. Calcium Antagonist-Induced Gingival Hyperplasia. <i>Ann Intern Med.</i> 1994;120(8):663-664.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/8135450/pubmed" id="8135450" target="_blank">8135450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.1">
<a name="FDA.1"></a>US Food and Drug Administration (FDA). FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. 2015. <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-strengthens-warning-non-aspirin-nonsteroidal-anti-inflammatory</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2688586">
<a name="2688586"></a>Wallin JD, Fletcher E, Ram CV, et al. Intravenous Nicardipine for the Treatment of Severe Hypertension. A Double-Blind, Placebo-Controlled Multicenter Trial. <i>Arch Intern Med.</i> 1989;149(12):2662-2669.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/2688586/pubmed" id="2688586" target="_blank">2688586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24341872">
<a name="24341872"></a>Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26. doi: 10.1111/jch.12237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/24341872/pubmed" id="24341872" target="_blank">24341872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22528277">
<a name="22528277"></a>Woloszyn AV, McAllen KJ, Figueroa BE, DeShane RS, Barletta JF. Retrospective evaluation of nicardipine versus labetalol for blood pressure control in aneurysmal subarachnoid hemorrhage. <i>Neurocrit Care</i>. 2012;16(3):376-380. doi: 10.1007/s12028-012-9700-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/22528277/pubmed" id="22528277" target="_blank">22528277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/nicardipine-pediatric-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12925 Version 457.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
